Basic science: (February 2009)

Abstract

1. Ang EZF, Nguyen HT, Sim HL, Putti TC, Lim LHK. Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. Mol Cancer Res 2009; 7: 266–274. 2. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009; 15: 778–787. 3. Brerner TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. Int J Cancer 2009; 124: 896–904. 4. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573–587. 5. Connors SK, Balusu R, Kundu CN, Jaiswal AS, Gairola CG, Narayan S. C/EBP b-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate. Oncogene 2009; 28: 921–932. 6. de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009; 101: 205–209. 7. Ford CE, Ekstroem EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 3919–3924. 8. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banha AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3(1) regulatory t cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009; 15: 1046–1051. 9. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen SL, Chang DK, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 2009; 15: 1317–1325. 10. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28: 843–853. 11. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, Hayran M, Shapiro CL. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 g expression levels correlate with basal phenotype in breast cancer. Cancer 2009; 115: 899–908. 12. Holm C, Kok M, Michalides R, Fles R, Koornstra RHT, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G, Linn SC. Phosphorylation of the oestrogen receptor a at serine 305 and prediction of tamoxifen resistance in breast cancer. J Path 2009; 217: 372–379. 13. Hong SW, Kim CJ, Park WS, Shin JS, Lee SD, Ko SG, Jung SI, Park IC, An SK, Lee WK, Lee WJ, Jin DH, Lee MS. p34(SEI-1) inhibits apoptosis through the stabilization of the xlinked inhibitor of apoptosis protein: p34(SEI-1) as a novel target for anti-breast cancer strategies. Cancer Res 2009; 69: 741–746. 14. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009; 106: 3372–3377. 15. Jin CY, Yang YA, Anver MR, Morris N, Wang XC, Zhang YE. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res 2009; 69: 735–740. First published online 14/07/09 BCO/851/2009/JW